Table 1.
Clinical features for patients with or without renal endpoints
| Clinical features | Renal endpoints reached | P value | |
|---|---|---|---|
| Yes | No | ||
| Number of patients | 30 | 245 | |
| Mean age (years) | 42 ± 22 | 33 ± 16 | 0.052 |
| Gender (Male/Female) | 21/9 | 122/123 | 0.036 |
| Extrarenal manifestation | |||
| Skin (n, %) | 30 (100%) | 245 (100%) | |
| Gastrointestinal tract (n, %) | 4 (13.3%) | 62 (24.3%) | 0.147 |
| Joints (n, %) | 1 (3.3%) | 45 (18.4%) | 0.068 |
| MAP (mmHg) | 100 ± 9 | 94 ± 11 | 0.012 |
| Scr (μmol/L) | 103.0 (74.8217.8) | 63.0 (53.0,78.0) | <0.001 |
| eGFR (ml/min/1.73m2) | 67.4 (30.1, 115.4) | 121.2 (92.6, 140.1) | <0.001 |
| Proteinuria(g/24 h) | 2.7 (1.0, 5.0) | 1.12 (0.6, 2.7) | <0.001 |
| Immunosuppressant therapy (n, %) | 24 (80.0%) | 176 (71.8%) | 0.343 |
| Steroids only(n) | 6 | 93 | 0.019 |
| Steroids + IVC/MMF(n) | 18 | 83 | |
| ACEI/ARB | 12 (40.0%) | 83 (33.9%) | 0.51 |
The data were expressed as mean ± s.d. or as numbers(percentage)
Results of Scr, eGFR, proteinuria were expressed as median (interquartile range)
MAP mean arterial pressure, Scr serum creatinine, eGFR estimated glomerular filtration rate, IVC intravenous cyclophosphamide, MMF mycophenolate mofetil, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker